Clinical Trial Update: Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients

View source ↗

Summary

A completed AstraZeneca-sponsored clinical study evaluating the prevalence of different HER2 levels and associated clinicopathologic features in Chinese breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer, HER2 | Status: COMPLETED